Zeolites for delivery of nitric oxide

US9402862B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9402862-B2
Application numberUS-87441710-A
CountryUS
Kind codeB2
Filing dateSep 2, 2010
Priority dateJul 3, 2003
Publication dateAug 2, 2016
Grant dateAug 2, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

There is described zeolites containing releasably adsorbed nitric oxide, methods of preparing the zeolites, methods of releasing the nitric oxide into a solution or into air and uses of the zeolites in therapy.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method of releasing nitric oxide (NO) at body or room temperature from a zeolites comprising extra-framework cations, the method comprising the steps of: (i) providing a partially or fully dehydrated aluminosilicate zeolites comprising extra-framwork cations selected from the group consisting of Fe, Cu, Ru, Rh, Co, Ni, Zn, and Ag, the extra-framework cations being effective to chemically bind nitric oxide and having nitric oxide bound thereto, (ii) contacting the zeolites from (i) with moisture at body or room temperature, whereby nitric oxide is displaced from the zeolites and released, wherein the providing step comprises administering the zeolites to an animal subject either inside the animal subject or topically, and the contacting and release of nitric oxide occurs either inside the animal body or topically, respectively. 2. The method according to claim 1 , wherein the moisture is comprised within blood of the animal subject. 3. The method of claim 1 , wherein the providing step comprises topically administering the zeolites to an animal subject. 4. The method according to claim 3 , wherein the zeolites is administered in conjunction with a surgical procedure. 5. The method according to claim 1 , wherein the zeolites has an LTA (Linde Type A/Zeolite A) framework structure. 6. The method according to claim 1 , wherein the zeolites is in the form of a powder or a monolith. 7. The method according to claim 6 , wherein said monolith is formed by compression of a zeolites powder or comprises a powdered zeolites and a binder. 8. The method according to claim 7 , where the binder is selected from ceramic binders and polymeric binders. 9. The method according to claim 1 wherein the zeolites in step (i) is provided in sealed airtight packaging which is removed prior to use in the contacting step. 10. The method according to claim 1 , wherein the animal subject possesses a disease or medical condition selected from the group consisting of infection of the skin; Raynaud's disease; possession of a wound; restenosis; psoriasis, eczema, skin cancer (melanoma); severe foot or body odor, and methicillin-resistant Staphylococcus aureus infection. 11. The method according to claim 1 , wherein the zeolites in step (ii) is provided as part of a medical article selected from the group consisting of a stent, a catheter, a wound dressing, a bandage, a self-adhesive plaster and a patch. 12. The method of claim 1 , for use in a cosmetic or personal hygiene treatment of an individual, wherein step (i) comprises providing the zeolites in the form of a cosmetic preparation, deodorant, depilatory, or hair preparation. 13. The method of claim 1 , wherein the zeolites has a framework structure selected from LTA (Linde Type A/zeolite A), FAU (faujasite), MFI (ZSM-5) MOR (mordenite), FER (ferrierite), BEA (zeolites beta), PHI (zeolites Phi) and SAS (STA-6/St. Andrews Six). 14. The method of claim 1 , wherein the providing step comprises administering the zeolites to an animal subject inside the animal subject.

Assignees

Inventors

Classifications

  • Drugs for disorders of the cardiovascular system · CPC title

  • Antibacterial agents · CPC title

  • Antineoplastic agents · CPC title

  • Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis · CPC title

  • Antivirals · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9402862B2 cover?
There is described zeolites containing releasably adsorbed nitric oxide, methods of preparing the zeolites, methods of releasing the nitric oxide into a solution or into air and uses of the zeolites in therapy.
Who is the assignee on this patent?
Morris Russell Edward, Wheatley Paul Stewart, Butler Anthony Robert, and 1 more
What technology area does this patent fall under?
Primary CPC classification A61K33/00. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Aug 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).